Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ABVX with free AI briefings, catalyst countdowns, and dilution alerts.

ABVX · ABIVAX Société Anonyme

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$402.4M Cash on Hand
24.5mo Cash Runway
4.8% Short Interest
$163.58 Analyst Target (12)
Follow ABVX by email Get an email when ABVX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ABVX, unsubscribe in one click. Privacy

📣 What ABVX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
ABX203 therapeutic Hepatitis B vaccine treatment Chronic Hepatitis B Phase 2/3 · NCT02249988 Completed
Obefazimod (ABX464) Ulcerative Colitis Phase 3 · NCT05535946 Active not recruiting
iNKT Cell Agonist ABX196 Carcinoma, Hepatocellular Phase 1/2 · NCT03897543 Completed
Fluvoxamine Healthy Phase 1 · NCT05121714 Completed
Obefazimod Minitablet 50 mg Healthy Phase 1 · NCT07453784 Recruiting

Also used in these trials (approved or third-party drugs, not ABVX's own candidates): Methotrexate, Caffeine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ABVX holds $402.4M in cash and short-term investments and burns about $49.3M/quarter from operations, an estimated runway of 24.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 7 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABVX files for a raise →

👥 Who Owns ABVX

Insiders Form 4 data not loaded yet Other 5%+ holders 11.1% Institutions (382 holders) 74.7% Public and other holders 14.2%
HolderTypeShares% of sharesAs of
Raymond Debbane 5%+ holder (13G) 4,825,759 6.14% 2026-06-30
Helikon Investments Ltd Institution (13F) 4,222,896 5.38% 2026-09-30
Darwin Global Management, Ltd. Institution (13F) 4,021,583 5.12% 2026-09-30
Vestal Point Capital, LP Institution (13F) 3,960,000 5.04% 2026-09-30
Invus Public Equities, L.P. 5%+ holder (13G) 3,922,995 5.00% 2025-12-31
TCG Crossover Management, LLC Institution (13F) 3,663,038 4.66% 2026-09-30
Janus Henderson Group Ltd. Institution (13F) 2,147,116 2.73% 2026-09-30
Adar1 Capital Management, LLC Institution (13F) 2,050,822 2.61% 2026-09-30
Westfield Capital Management Co LP Institution (13F) 1,651,819 2.10% 2026-09-30
Caligan Partners, LP Institution (13F) 1,557,924 1.98% 2026-09-30
Morgan Stanley Institution (13F) 1,437,880 1.83% 2026-09-30
Citadel Advisors Llc Institution (13F) 1,308,467 1.67% 2026-09-30

Share count 78,536,412 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ABVX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABVX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.